Biofabricated the patient-specific tumor-on-a-chip system for medical prediction

Source： Ever Supreme Bio Technology Co.,Ltd. ( Healthcare+ Expo- booth no.：M733)

The key technology of Patient Derived Tumor Spheroids (PDTS) is to create an in-vitro patient tumor microenvironment and tumor-like properties, furthermore, predict various cancer antidrug effectiveness to each patient via the high-throughput and high-quality cell viability detection and biomarker analysis. Therefore, this project established several technologies including extracellular matrix fabrication, bioink design, cell population identification, and tumor physiological environment for the upon goal.

The spheroids owned advantages including of uniform size, high similarity of cell heterogeneity with patient's tumor, hypoxia gradient, and consistent cell quantity in each spheroid. The gene expression profile of patient-derived spheroids showed significant correlation with original biopsies which reflects to the real tumor microenvironment and cancer drug screening results. Based on 15 clinical cases, the PDTS test achieved 84.6% of sensitivity, 100% of specificity, and 86.6% of accuracy. This test service will soon be accredited to ISO 15189 standard.